d glucose level Novo Nordisk ® Semaglutide holds a plethora of therapeutic opportunities 1 Diabetes FOCUS - Diabetic retinopathy outcomes trial Semaglutide s.c; ~1,500 patients, T2D ≥10 years CVD SOUL - Cardiovascular outcomes trial Oral semaglutide; ~9,600 patients, T2D, established CVD or CKD Obesity SELECT – Cardiovascular outcomes trial Semaglutide 2.4 mg, ~17,500 patients with obesity and without diabetes, event driven NASH Semaglutide in NASH Semaglutide s.c.; phase 3 and 2 trials CKD FLOW - Chronic kidney disease outcomes trial Semaglutide 1.0 mg; ~3,200 patients, T2D, moderate to severe CKD PAD STRIDE – Peripheral artery disease trial Semaglutide 1.0 mg; ~ 800 patients with T2D and PAD Brain Alzheimer’s Disease disorders Oral Semaglutide 14 mg; ~ 3,700 patients with early Alzheimer’s disease Heart Failure STEP – HFpEF Semaglutide 2.4 mg; ~ 600 patients with obesity-related HFpEF patitis; PAD: Peripheral artery disease
Download PDF file